Article
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
Antimicrobial agents and chemotherapy - 1 Feb 2008
Lambert-Niclot Sidonie, Flandre Philippe, Canestri Ana, Peytavin Gilles, Blanc Christine, Agher Rachid, Soulié Cathia, Wirden Marc, Katlama Christine, Calvez Vincent, Marcelin Anne-Geneviève
Abstract excerpt
The objective of this study was to characterize the mutations selected by darunavir (DRV) use in protease inhibitor (PI)-experienced patients and the associated factors. We analyzed treatment failure in 54 PI-experienced human immunodeficiency virus (HIV)-infected patients on a DRV- and ritonavir-containing regimen. Viral genotyping was carried out at the baseline, at between 1 and 3 months of treatment, and at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.